Zobrazeno 1 - 10
of 52
pro vyhledávání: '"Sufey Ong"'
Autor:
Domenico Mallardo, Mario Fordellone, Andrew White, Margaret Ottaviano, Francesca Sparano, Michael Bailey, Arianna Bianca Facchini, Sufey Ong, Piera Maiolino, Corrado Caracò, Sarah Church, Ernesta Cavalcanti, Sarah Warren, Alfredo Budillon, Alessandra Cesano, Ester Simeone, Paolo Chiodini, Paolo Antonio Ascierto
Publikováno v:
Journal of Translational Medicine, Vol 21, Iss 1, Pp 1-13 (2023)
Abstract Background Identifying response markers is highly needed to guide the treatment strategy in patients with metastatic melanoma. Methods A retrospective study was carried out in patients with unresectable/metastatic melanoma (stage IIIb–IV),
Externí odkaz:
https://doaj.org/article/6a0f6b12d40a45cdad984752d02e73b2
Autor:
Michael Bailey, Andrew White, Francesca Sparano, Alessandra Cesano, Corrado Caracò, Ester Simeone, Alfredo Budillon, Sarah Warren, SuFey Ong, Domenico Mallardo, Sarah Church, Ernesta Cavalcanti, Paolo Ascierto, Margaret Ottaviano, Paolo Chiodini, Piera Maiolino, Mario Fordellone, Bianca Arianna Facchini
Publikováno v:
Journal for ImmunoTherapy of Cancer, Vol 11, Iss Suppl 1 (2023)
Externí odkaz:
https://doaj.org/article/27910087b747468b892288cebab2428c
Autor:
Ester Simeone, Giosuè Scognamiglio, Mariaelena Capone, Diana Giannarelli, Antonio M. Grimaldi, Domenico Mallardo, Gabriele Madonna, Marcello Curvietto, Assunta Esposito, Fabio Sandomenico, Francesco Sabbatino, Nicholas L. Bayless, Sarah Warren, SuFey Ong, Gerardo Botti, Keith T. Flaherty, Soldano Ferrone, Paolo A. Ascierto
Publikováno v:
Journal of Translational Medicine, Vol 19, Iss 1, Pp 1-10 (2021)
Abstract Background Studies carried out in vitro and in a mouse model have shown that BRAF inhibitors enhance the effects of IFN-α on BRAFV600E melanoma cells through the inhibition of ERK. Therefore, the combination of vemurafenib and IFN-α in pat
Externí odkaz:
https://doaj.org/article/86e55258d57a4fdc9a2470824a69f5e9
Publikováno v:
Journal for ImmunoTherapy of Cancer, Vol 7, Iss 1, Pp 1-12 (2019)
Abstract Background Clinical benefit from checkpoint inhibitors has been associated in a tumor-agnostic manner with two main tumor traits. The first is tumor antigenicity, which is typically measured by tumor mutation burden, microsatellite instabili
Externí odkaz:
https://doaj.org/article/6bc20fbb53a1452c80c8676d76885764
Autor:
Kathrin Renner, Christina Bruss, Annette Schnell, Gudrun Koehl, Holger M. Becker, Matthias Fante, Ayse-Nur Menevse, Nathalie Kauer, Raquel Blazquez, Lisa Hacker, Sonja-Maria Decking, Toszka Bohn, Stephanie Faerber, Katja Evert, Lisa Aigle, Sabine Amslinger, Maria Landa, Oscar Krijgsman, Elisa A. Rozeman, Christina Brummer, Peter J. Siska, Katrin Singer, Stefanie Pektor, Matthias Miederer, Katrin Peter, Eva Gottfried, Wolfgang Herr, Ibtisam Marchiq, Jacques Pouyssegur, William R. Roush, SuFey Ong, Sarah Warren, Tobias Pukrop, Philipp Beckhove, Sven A. Lang, Tobias Bopp, Christian U. Blank, John L. Cleveland, Peter J. Oefner, Katja Dettmer, Mark Selby, Marina Kreutz
Publikováno v:
Cell Reports, Vol 29, Iss 1, Pp 135-150.e9 (2019)
Summary: Tumor-derived lactic acid inhibits T and natural killer (NK) cell function and, thereby, tumor immunosurveillance. Here, we report that melanoma patients with high expression of glycolysis-related genes show a worse progression free survival
Externí odkaz:
https://doaj.org/article/ca9683bbded745c68d1cf4f71ab912e4
Autor:
Caroline Robert, Stéphan Vagner, Jean-Yves Scoazec, Pascale Morel, SuFey Ong, Kristina Sorg, Sarah Warren, Jéremy Lupu, Emilie Routier, Sara Faouzi, Caroline Brard, Séverine Roy, Shensi Shen, Julien Adam, Isabelle Girault
Results of PLA, CD8 and PDL1 (MELscore) in all the samples
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::3aa5d3e7b4d771f42fe8667c88c0ea8d
https://doi.org/10.1158/1078-0432.22482161.v1
https://doi.org/10.1158/1078-0432.22482161.v1
Autor:
Caroline Robert, Stéphan Vagner, Jean-Yves Scoazec, Pascale Morel, SuFey Ong, Kristina Sorg, Sarah Warren, Jéremy Lupu, Emilie Routier, Sara Faouzi, Caroline Brard, Séverine Roy, Shensi Shen, Julien Adam, Isabelle Girault
Purpose:Less than 50% of patients with melanoma respond to anti–programmed cell death protein 1 (anti–PD-1), and this treatment can induce severe toxicity. Predictive markers are thus needed to improve the benefit/risk ratio of immune checkpoint
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::130342ef5b960dbb0ebd0956b86de8bf
https://doi.org/10.1158/1078-0432.c.6530840
https://doi.org/10.1158/1078-0432.c.6530840
Autor:
Caroline Robert, Stéphan Vagner, Jean-Yves Scoazec, Pascale Morel, SuFey Ong, Kristina Sorg, Sarah Warren, Jéremy Lupu, Emilie Routier, Sara Faouzi, Caroline Brard, Séverine Roy, Shensi Shen, Julien Adam, Isabelle Girault
Supplementary Figure Legends
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::d847eb45cb025e855425a9ce83ec5e1d
https://doi.org/10.1158/1078-0432.22482167
https://doi.org/10.1158/1078-0432.22482167
Autor:
Caroline Robert, Stéphan Vagner, Jean-Yves Scoazec, Pascale Morel, SuFey Ong, Kristina Sorg, Sarah Warren, Jéremy Lupu, Emilie Routier, Sara Faouzi, Caroline Brard, Séverine Roy, Shensi Shen, Julien Adam, Isabelle Girault
Kaplan Meier representation of the progression-free survival (PFS) and overall survival (OS) for PDL1, CD8, TIS and Melscore variables in all samples (exploratory and validation cohorts) with a recapitulive table of survival medians (NA : Not Availab
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::0eccd81f44e2537fc5aa6d59e7ceb6dd
https://doi.org/10.1158/1078-0432.22482170.v1
https://doi.org/10.1158/1078-0432.22482170.v1
Autor:
Gabe S. Sonke, Ferry Lalezari, Leonie Voorwerk, John B. A. G. Haanen, SuFey Ong, T. Wiersma, Noor A. M. Bakker, Philip C. Schouten, Ton N. Schumacher, Harm van Tinteren, Inge Kemper, Karin E. de Visser, Nicola S. Russell, Hugo M. Horlings, Karolina Sikorska, Maarten Slagter, Marleen Kok, Sarah Warren, I.A.M. Mandjes, Erik van Werkhoven, Myriam Chalabi, Michiel de Maaker, Dennis Peters, Sofie Wilgenhof, Iris Nederlof, Sabine C. Linn, Suzanne Onderwater, Charlotte A.H. Lange, Roelof J.C. Kluin, Roberto Salgado, Koen Van de Vijver, Lodewyk F. A. Wessels, Steven L. C. Ketelaars, Christian U. Blank
Publikováno v:
Nature medicine, 25(6), 920-928. Nature Publishing Group
The efficacy of programmed cell death protein 1 (PD-1) blockade in metastatic triple-negative breast cancer ( TNBC ) is low1–5, highlighting a need for strategies that render the tumor microenvironment more sensitive to PD-1 blockade. Preclinical r
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::6fb564fecd574761cf9b4e83bd8b032d
https://www.scopus.com/inward/record.uri?partnerID=HzOxMe3b&scp=85065759990&origin=inward
https://www.scopus.com/inward/record.uri?partnerID=HzOxMe3b&scp=85065759990&origin=inward